Changing of the vascular endothelial growth factor concentration in aqueous humor before and after intravitreal injection of Bevacizumab adjuvant treating complicated proliferative diabetic retinopathy.

Abstract

This article studies the changing of concentration of vascular endothelial growth factor (VEGF) from the aqueous humor sample, before and after intravitreal injection of Bevacizumab, for treatment of complicated proliferative diabetic retinopathy (PDR) and the correlation with clinical features. This study was implemented with prospective and interventional case series; 1.25 mg of Bevacizumab was injected into the vitreous cavity to treat PDRin 48 eyes of 29 patients. Aqueous humor samples were obtained before intravitreal injection of Bevacizumab and one week after. Study results showed: VEGF concentration decreased from 474.23±361.32 pg/ml to 16.96±18.11 pg/ml (p=0.000) at all eyes after one-week injection. There were no differences in levels of VEGF among groups according to the vitreous haemorrhage, tractional retinal detachment, and retinal fibrosis. Therefore, the study exhibited a better understanding of the role of anti-VEGF in the adjuvant treatment of complicated PDR.